1,671,204 + 1,515,877 − 1,254,914Saudi Aramco
Saudi Arabian Oil CompanyChange company
Operating cash-flow DCF
Projects cash flow from operating earnings after royalties. The starting margin removes the reported PRefChem sale gain. September cash, investments, borrowings and minority interests convert operating value to shareholder value.
Earnings basis & source figures
Uses FY2025 plus 9M 2026 minus 9M 2025. Starting operating income excludes the SAR 25,902m PRefChem disposal gain and retains reported impairment. Earlier operating results include activity before the sale, so the model is a trailing benchmark. The bridge uses the September 30 balance sheet after the sale.
Review figures and sources ↓Values are per share. Lower and higher growth keep your other edits and change initial growth within the funding limit. Starting assumptions resets the model assumptions.
Reported cash flow and investment
Figures use FY2025 + 9M 2026 − 9M 2025. The model estimates future cash flow from operating margin, tax and reinvestment.
What changed in the September model
- The model removes the SAR 25.9bn PRefChem disposal gain from the starting margin. Trailing earnings still include operations before the sale. Disposal note ↗
- The starting earnings retain SAR 25.4bn of trailing impairment and remeasurement losses.
- The HUMAIN contribution and Q3 dividend declaration followed the model date. Filing notes ↗
At the reporting date—not a live price target or recommendation.
Compare periods
TTM TO SEP 2026 · The first point is the editable model anchor (derived from the selected earnings basis); hatched bars are forecasts. Hover, tap or use arrow keys to inspect. Drag across periods to compare. Projected cash flows are not announced distributions.
From cash flows to share value · SAR millions
Valuation sensitivity
Select a cell to apply its discount rate and terminal growth together.
| Discount / growth | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 9.00% | |||||
| 9.50% | |||||
| 10.00% | |||||
| 10.50% | |||||
| 11.00% |
What does the price imply?
Enter a reference price and date to see which assumption would match it with all other inputs held fixed.
Add a positive price and its date to calculate the result.
- Current model input
- 3%
- Solver range
- -49.99% – 50%
Value per share by assumption
Revenue growthBars show scenarios around your current assumption.
Year-by-year forecast
SAR millions. Reinvestment funds growth; it is not an additional operating expense.
| Year ending | NOPAT | Reinvestment | Cash flow | Discount factor | Present value |
|---|---|---|---|---|---|
| 2027-09-30 | 446,266.05 | 64,990.2 | 381,275.85 | 0.9091 | 346,614.41 |
| 2028-09-30 | 459,406.11 | 68,756.11 | 390,650 | 0.8264 | 322,851.24 |
| 2029-09-30 | 472,677.84 | 72,832.68 | 399,845.16 | 0.7513 | 300,409.59 |
| 2030-09-30 | 486,070.38 | 77,264.65 | 408,805.73 | 0.6830 | 279,219.81 |
| 2031-09-30 | 499,572.33 | 82,106.48 | 417,465.85 | 0.6209 | 259,213.45 |
| 2032-09-30 | 513,171.8 | 87,425.16 | 425,746.64 | 0.5645 | 240,322.88 |
| 2033-09-30 | 526,856.38 | 93,303.96 | 433,552.42 | 0.5132 | 222,480.94 |
| 2034-09-30 | 540,613.19 | 99,847.78 | 440,765.41 | 0.4665 | 205,620.31 |
| 2035-09-30 | 554,428.86 | 107,190.55 | 447,238.31 | 0.4241 | 189,672.7 |
| 2036-09-30 | 568,289.58 | 115,506.01 | 452,783.57 | 0.3855 | 174,567.67 |
Formulas & reconciliation
Revenueₜ = Revenueₜ₋₁ × (1 + growthₜ). NOPATₜ = Revenueₜ × margin × (1 − tax). Reinvestmentₜ = (NOPATₜ − NOPATₜ₋₁) ÷ ROICₜ. FCFFₜ = NOPATₜ − reinvestmentₜ.
PVₜ = cash flowₜ ÷ (1 + discount rate)ᵗ. Terminal value = terminal cash flow ÷ (discount rate − terminal growth). PV of terminal = terminal value ÷ (1 + discount rate)ᴺ.
Terminal cash = NOPATᴺ × (1 + g) − (NOPATᴺ × g ÷ terminal ROIC). Share value = (PV of FCFF + PV of terminal + cash + investments − debt − minority claims + other adjustments) ÷ shares.
Analyst estimates
Published outlooks and past results
Forward analyst estimates
Aljazira Capital · Source date
- FY2026E
- 2,078,000
Values in SAR millions. This snapshot reflects the date shown. DCF assumptions are set separately.
Every number, with its source
Reported inputs below are converted to SAR millions where needed. Page references are PDF page numbers.
706,822 + 660,951 − 551,973815,800 − 25,902789,898 ÷ 1,932,167 × 100368,082 ÷ 815,263 × 10078,165 + 42,354 + 89,780 + 13,844310,601 + 49,409508,996 − 184,357| Reported input | Period | Value | Unit | Source |
|---|---|---|---|---|
| Revenue and other income related to sales | FY2025 | 1,671,204 | SAR m | Page 14 ↗ |
| Revenue and other income related to sales | 9M 2026 | 1,515,877 | SAR m | Page 27 ↗ |
| Revenue and other income related to sales | 9M 2025 comparative | 1,254,914 | SAR m | Page 27 ↗ |
| Operating income | FY2025 | 706,822 | SAR m | Page 14 ↗ |
| Operating income | 9M 2026 | 660,951 | SAR m | Page 27 ↗ |
| Operating income | 9M 2025 comparative | 551,973 | SAR m | Page 27 ↗ |
| Income taxes and zakat expense | FY2025 | 352,650 | SAR m | Page 14 ↗ |
| Income taxes and zakat expense | 9M 2026 | 282,811 | SAR m | Page 27 ↗ |
| Income taxes and zakat expense | 9M 2025 comparative | 267,379 | SAR m | Page 27 ↗ |
| Income before income taxes and zakat | FY2025 | 702,860 | SAR m | Page 14 ↗ |
| Income before income taxes and zakat | 9M 2026 | 663,362 | SAR m | Page 27 ↗ |
| Income before income taxes and zakat | 9M 2025 comparative | 550,959 | SAR m | Page 27 ↗ |
| PRefChem disposal gainThe gain includes derecognized net liabilities and additional receivables. It is removed once from the starting operating margin. | 9M 2026 | 25,902 | SAR m | Page 42 ↗ |
| Impairment and held-for-sale remeasurement losses | FY2025 | 32,425 | SAR m | Page 14 ↗ |
| Impairment and held-for-sale remeasurement losses | 9M 2026 | 1,908 | SAR m | Page 27 ↗ |
| Impairment and held-for-sale remeasurement losses | 9M 2025 comparative | 8,886 | SAR m | Page 27 ↗ |
| Cash and cash equivalents | 30 Sep 2026 | 143,518 | SAR m | Page 29 ↗ |
| Joint ventures and associates | 30 Sep 2026 | 78,165 | SAR m | Page 29 ↗ |
| Non-current securities | 30 Sep 2026 | 42,354 | SAR m | Page 29 ↗ |
| Current securities | 30 Sep 2026 | 89,780 | SAR m | Page 29 ↗ |
| Short-term investments | 30 Sep 2026 | 13,844 | SAR m | Page 29 ↗ |
| Non-current borrowings | 30 Sep 2026 | 310,601 | SAR m | Page 29 ↗ |
| Current borrowings | 30 Sep 2026 | 49,409 | SAR m | Page 29 ↗ |
| Lease liabilities included in borrowingsIncluded in the borrowing total. | 30 Sep 2026 | 58,282 | SAR m | Page 38 ↗ |
| Non-controlling interests | 30 Sep 2026 | 222,830 | SAR m | Page 29 ↗ |
| Issued ordinary shares including treasury | FY2025 | 242,000 | m shares | Page 19 ↗ |
| Operating cash flow | FY2025 | 510,798 | SAR m | Page 18 ↗ |
| Operating cash flow | 9M 2026 | 355,835 | SAR m | Page 31 ↗ |
| Operating cash flow | 9M 2025 comparative | 357,637 | SAR m | Page 31 ↗ |
| Capital expenditure | FY2025 | 190,444 | SAR m | Page 18 ↗ |
| Capital expenditure | 9M 2026 | 134,211 | SAR m | Page 31 ↗ |
| Capital expenditure | 9M 2025 comparative | 140,298 | SAR m | Page 31 ↗ |
| Post-period HUMAIN cash contributionThe acquisition closed after the September model date. September cash and investments are the bridge inputs. | 1 Nov 2026 | 9,892 | SAR m | Page 43 ↗ |
| Post-period base dividend declaredThe filing states this dividend will be deducted in the fourth quarter. This is the board declaration date. | 2 Nov 2026 | 82,068 | SAR m | Page 43 ↗ |
Edit the enterprise-to-equity bridge
The source facts above never change. These are model overrides only. Enter an additional present-value cost as negative or asset as positive; it applies once, without changing recurring profit or book growth. Do not deduct an already recorded provision, liability or approved dividend again.